Kopran

A Global Pharmaceutical Company

Kopran

A Global Pharmaceutical Company

Bulk Drugs


API's Category Specifications Regulatory Status

Atenolol

Anti-Hypertensive

IP/BP/EP/USP

CEP, EU GMP, USDMF

Amlodipine Besylate

Anti-Hypertensive

IP/BP/EP/USP

DMF Available

Metoprolol Succinate

Anti-Hypertensive

IP/BP/EP/USP

DMF Available, USDMF filed

Metoprolol Tartrate

Anti-Hypertensive

IP/BP/EP/USP

DMF Available, USDMF filed

Roxithromycin

Macrolides

IP/BP/EP

CEP, KFDA

Azithromycin

Macrolides

IP/BP/EP/USP

CEP, USDMF filed

Clarithromycin Granules 27.5%

Macrolides

In-House

DMF Available

Clarithromycin Granules 33%

Macrolides

In-House

 

Clarithromycin Granules 43%

Macrolides

In-House

DMF Available

Pregabalin

Neuromodulator

IP/EP/In-House

CEP, USDMF filed

Ceftriaxone Sodium

Sterile Cephalosporins

IP/BP/EP/USP

DMF Available

Cefotaxime Sodium

Sterile Cephalosporins

IP/BP/EP/USP

DMF Available

Cefepime (with L-Arginine) for Injection

Sterile Cephalosporins

IP/USP

 

Meropenem (with Sodium Carbonate) for Injection

Carbapenems

IP/USP

DMF Available

Doripenem

Carbapenems

In-House

DMF Available

Biapenem

Carbapenems

In-House

DMF Available

Lymecycline

Anti-Acne,

Anti-Infective

EP

DMF Available, CEP filed

Nitroxoline

Antibiotic

In-House

DMF Available

Ticagrelor

Anti-Thrombotic

IP / EP/ USP/ In-House

DMF under preparation

Rivaroxaban

Anti-Thrombotic

IP / EP/ USP/ In-House

DMF under preparation

Apixaban

Anti-Thrombotic

In-House

DMF under preparation

Empagliflozin

Anti-Diabetic

In-House

DMF under preparation

Dapagliflozin Propanediol Monohydrate

Anti-Diabetic

In-House

DMF under preparation

Faropenem

Carbapenems

JP/In-House

DMF under preparation

Tebipenem

Carbapenems

In-House

DMF under preparation

Pellets Category

Duloxetine Pellets 17%, 21.5%

Anti-Depressent

Venlafaxine Pellets 33%

Anti-Depressent

Dexlansoprazole Pellets 20%, 23%

Proton Pump Inhibitor

API's Category R&D Sample availability R&D Tech pack availability Specifications

Canagliflozin Hemihydrate

Anti-Diabetic

Available

Available

In-House

Ertapenem

Carbapenems

Available

Available

In-House

Imipenem
(Non-Sterile)

Carbapenems

Nov 2022

Dec 2022

In-House

Montelukast Sodium

Anti-asthmatics

Available

Under Lab Development

IP/EP/USP

Ketoconazole

Anti-fungal

Oct 2022

Under Lab Development

IP/EP/USP

Clopidogrel Bisulphate

Cardiovascular

Nov 2022

Under Lab Development

IP/EP/USP

Nitrofurantoin Monohydrate

To treat urinary tract infection

Nov 2022

Under Lab Development

IP/EP/USP

Nitrofurantoin Anhydrous

To treat urinary tract infection

Nov 2022

Under Lab Development

IP/EP/USP

Nitrofurantoin Macro crystal

To treat urinary tract infection

Nov 2022

Under Lab Development

IP/EP/USP

Rosuvastatin calcium

Lipid-Lowering Agents

Available

Under Lab Development

IP/EP/USP

Lacosamide

Anticonvulsants

Nov 2022

Under Lab Development

EP/USP

Buspirone Hydrochloride

Antianxiety Agents

Jan 2023

Under Lab Development

IP/EP/USP

Macitentan

To treat pulmonary arterial hypertension

Feb 2023

Under Lab Development

In-House

Riociguat

To treat pulmonary hypertension

Mar 2023

Under Lab Development

EP/USP

Edoxaban Tosylate

Anticoagulant

Oct 2022

Under Lab Development

In-House

Ertugliflozin L-pyroglutamic Acid

Anti-Diabetic

Mar 2023

Under Lab Development

In-House

Hypromellose Acetate Succinate (HPMCAS)

Excipient/ Coating material

Jun 2024

Aug 2024

USP / EP


Note


  • Products will not be offered for sale in countries where valid Patents are in force.
  • It is the responsibility of the buyer to comply with the above.


For more information on APIs, send an e-mail to: api@kopran.com